Related Experiment Video

Updated: Jan 29, 2026

Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation
18:08

Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation

Published on: December 31, 2007

10.3K

A Potent CD1d-binding Glycolipid for iNKT-Cell-based Therapy Against Human Breast Cancer

Toshiyuki Seki1,2, Jianyun Liu3, Randy R Brutkiewicz3

  • 1Aaron Diamond AIDS Research Center, Affiliate of The Rockefeller University, New York, NY, U.S.A.

Anticancer Research
|February 4, 2019
PubMed
Abstract

Insights

This study shows that a glycolipid, 7DW8-5, effectively activates invariant natural killer T-cells (iNKT) to eliminate human breast cancer cells. This novel immunotherapy demonstrates potent antitumor effects in both laboratory and animal models.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Invariant natural killer T-cells (iNKT) show promise in cancer therapy.
  • Breast cancer remains a significant health challenge with high recurrence rates.
  • Targeting CD1d-expressing cells with glycolipids is a potential therapeutic strategy.

Purpose of the Study:

  • To evaluate the antitumor efficacy of the CD1d-binding glycolipid 7DW8-5.
  • To assess the in vitro and in vivo effects of 7DW8-5 on human breast cancer cells.
  • To investigate the role of iNKT cells in mediating these effects.

Main Methods:

  • Human breast cancer cells (MDA-MB-231) engineered to express CD1d were co-cultured with human iNKT cells.
  • In vitro cytotoxicity was assessed by measuring active caspase-3 levels.
  • In vivo studies involved injecting CD1d+ MDA-MB-231 cells into NSG mice, followed by iNKT cell and 7DW8-5 administration, with tumor growth monitored via luminescence.

Main Results:

  • 7DW8-5 enabled human iNKT cells to effectively kill CD1d-expressing breast cancer cells in vitro.
  • Unlike α-GalCer, 7DW8-5 demonstrated significant tumoricidal activity.
  • In vivo, 7DW8-5 combined with iNKT cells markedly inhibited the growth of human breast cancer xenografts in mice.

Conclusions:

  • CD1d-binding glycolipid-based iNKT-cell therapy presents a potent treatment strategy for breast cancer.
  • The findings support the clinical potential of 7DW8-5 for breast cancer treatment.
  • This approach offers a novel avenue for combating invasive breast cancer.
Keywords:
CD1dNatural killer T-cellglycolipidimmunodeficient miceimmunotherapyinvasive human breast cancer

More Related Videos

Invasive Behavior of Human Breast Cancer Cells in Embryonic Zebrafish09:22

Invasive Behavior of Human Breast Cancer Cells in Embryonic Zebrafish

Published on: April 25, 2017

17.4K
Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples07:03

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Published on: October 2, 2020

5.1K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
15.0K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
Nuclear Binding Energy02:13

Nuclear Binding Energy

The difference between the calculated and experimentally measured masses is known as the mass defect of the atom. In the case of helium-4, the mass defect indicates a “loss” in mass of 4.0331 amu – 4.0026 amu = 0.0305 amu. The loss in mass accompanying the formation of an atom from protons, neutrons, and electrons is due to the conversion of that mass into energy that is evolved as the atom forms. The nuclear binding energy is the energy produced when the atoms’ nucleons are bound...
14.8K
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.6K